Amyotrophic Lateral Sclerosis (ALS), frequently referred to as Lou Gehrig’s disease, is a neurodegenerative condition that progressively weakens muscles and impacts physical function. The ALS Program at Hospital for Special Surgery, a certified Center of Excellence, provides comprehensive care, including telehealth options, cutting-edge treatments, and participation in research and clinical trials for individuals facing this challenging disease. This article delves into ALS, focusing particularly on what to expect in terms of life expectancy following a diagnosis.
What is Amyotrophic Lateral Sclerosis (ALS)?
ALS is a progressive disease that targets motor neurons, the nerve cells responsible for controlling voluntary muscle movements. These motor neurons extend from the brain, through the brainstem and spinal cord, to muscles throughout the body, governing movement in the arms, legs, chest, throat, and mouth. In ALS, these critical neurons degenerate and die, leading to muscle wasting. Importantly, ALS does not impair sensory functions or cognitive abilities; sensory neurons and mental faculties remain unaffected.
ALS is generally classified into two categories: Upper Motor Neuron Disease, affecting neurons in the brain, and Lower Motor Neuron Disease, impacting nerves stemming from the spinal cord or brainstem. Both types involve damage and eventual loss of motor neurons, and tragically, ALS is a fatal condition.
ALS Life Expectancy: What to Expect After Diagnosis
A frequently asked question after an ALS diagnosis is, “Als How Long From Diagnosis To Death?” It’s crucial to understand that ALS progression varies significantly among individuals, making it challenging to predict an exact timeline. However, medical statistics provide an average outlook.
The median ALS life expectancy following diagnosis ranges from two to five years. While this average can be concerning, it’s important to remember that this is just an average. Approximately half of those diagnosed with ALS live for at least three years post-diagnosis. Encouragingly, around 25% survive for five years or more, and up to 10% may live for more than a decade. Remarkably, some individuals with ALS live considerably longer, like the renowned physicist Stephen Hawking, who lived for over fifty years after his diagnosis.
These statistics highlight the spectrum of ALS prognosis. Factors influencing survival time are still being researched, but they underscore that while ALS is a serious condition, the course of the disease is not uniform, and extended survival is possible for many.
Understanding ALS Symptoms and Progression
The diverse nature of ALS stems from the varying proportions of upper and lower motor neurons affected in each individual. This results in a wide range of initial symptoms and rates of disease progression. Despite these differences, progressive muscle weakness and paralysis are universal experiences for everyone with ALS. As ALS advances, more nerve cells become affected. Muscle tissue deteriorates, leading to muscle weakness and atrophy, often visibly thinning limbs. Paradoxically, muscles can also become spastic, leading to involuntary movements and increased muscle tone in certain areas of the body.
Early ALS symptoms can be subtle and easily overlooked. Common initial indicators include:
- Muscle weakness in hands, arms, or legs
- Impaired use of limbs
- Muscle twitching and cramping, particularly in hands and feet
- Weakness in muscles controlling speech, swallowing, or breathing
- Slowed or slurred speech (dysarthria or “thick speech”) and difficulty projecting voice
In later stages, ALS leads to significant breathing difficulties and swallowing problems, complications that are frequently the ultimate cause of death in ALS patients.
The Complex Causes of ALS
While the precise cause of ALS remains elusive, current research suggests a complex interplay of multiple factors contributing to motor neuron degeneration. Specific risk factors are still under investigation, with ongoing research exploring genetic and environmental influences. A 2009 study indicated that tobacco smoking might elevate ALS risk.
Potential contributing factors under investigation include:
- Defective glutamate metabolism
- Free radical injury
- Mitochondrial dysfunction
- Gene defects
- Programmed cell death (apoptosis)
- Cytoskeletal protein defects
- Autoimmune and inflammatory mechanisms
- Accumulation of protein aggregates (clumps)
- Viral infections
Genetic mutations and inherited traits are also likely to play a role in modifying disease susceptibility and progression.
Who is Affected by ALS?
In the United States, approximately 60% of reported ALS cases are men, and 93% of patients are Caucasian. US population studies indicate over 5,600 new ALS diagnoses annually – roughly 15 new cases daily. It’s estimated that about 30,000 Americans live with ALS at any given time. The majority of individuals develop ALS between 40 and 70 years of age, with an average diagnosis age of 55. However, younger individuals in their 20s and 30s can also, though rarely, be affected.
Diagnosing ALS: A Comprehensive Approach
ALS diagnosis is challenging because no single definitive medical test exists. Furthermore, many neurological conditions present with similar symptoms, necessitating the exclusion of other possibilities through clinical examinations and various medical tests. A thorough diagnostic process typically includes:
- Electrodiagnostic tests: Electromyography (EMG) and Nerve Conduction Velocity (NCV) studies to evaluate bulbar (speech and swallowing), cervical (arms, diaphragm), thoracic (breathing muscles), and lumbar (legs) regions.
- Blood and urine studies: Including serum protein electrophoresis, thyroid and parathyroid hormone levels, and 24-hour urine collection for heavy metals, to rule out immunological or inflammatory diseases.
- Spinal tap
- Imaging: X-rays, Magnetic Resonance Imaging (MRI), and CT scans, particularly of the cervical spine.
- Muscle and/or nerve biopsy
- Comprehensive neurological examination
The specific tests conducted are determined by the physician based on physical examination findings and previous medical test results.
Is There a Cure for ALS?
Currently, there is no known cure for ALS, and no treatment can reverse the damage it causes. However, treatments are available to help slow disease progression and manage symptoms.
ALS Treatment and Management Strategies
ALS treatment focuses on two primary areas: medications to potentially slow disease progression and multidisciplinary care to support patients and families in navigating the complexities of living with ALS. Multidisciplinary teams, comprising various specialists, utilize therapies and assistive devices to manage symptoms, maintain independence, and enhance quality of life. This comprehensive approach has been shown to improve survival rates for individuals with ALS.
ALS Medications and Clinical Trials
Two FDA-approved medications, riluzole (Rilutek, Teglutik) and edaravone (Radicava), have demonstrated a modest ability to slow ALS progression. Additionally, numerous promising clinical trials are underway globally, seeking to identify more effective strategies to combat ALS.
Assistive Devices and Therapeutics for Daily Living
A range of treatments and interventions are employed to assist individuals with ALS, including:
-
Proper body positioning techniques
-
Exercise regimens, physical and occupational therapy
-
Walking aids and support devices
-
Braces and splints for limb support
-
Customized wheelchairs
-
Home modifications for accessibility
-
Communication technology devices
-
Dietary recommendations for easier swallowing and nutritional support
-
Feeding tubes
-
Diaphragm pacers
-
Breathing support devices
Many individuals with ALS choose to participate in research studies to advance the understanding and treatment of this disease. Resources like the US National Institutes of Health Clinical Trials Registry and the HSS ALS Program provide further information on research opportunities.
(Return to top.)
References
- Dean KE, Shen B, Askin G, Schweitzer AD, Shahbazi M, Wang Y, Lange D, Tsiouris AJ. A specific biomarker for amyotrophic lateral sclerosis: Quantitative susceptibility mapping. Clin Imaging. 2021 Jul;75:125-130. doi: 10.1016/j.clinimag.2020.12.018. Epub 2021 Jan 4. PMID: 33548870.
- Shtilbans A, Choi SG, Fowkes ME, Khitrov G, Shahbazi M, Ting J, Zhang W, Sun Y, Sealfon SC, Lange DJ. Differential gene expression in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Jul;12(4):250-6. doi: 10.3109/17482968.2011.560946. Epub 2011 Mar 4. PMID: 21375368.
- Schweitzer AD, Liu T, Gupta A, Zheng K, Seedial S, Shtilbans A, Shahbazi M, Lange D, Wang Y, Tsiouris AJ. Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosis. AJR Am J Roentgenol. 2015 May;204(5):1086-92. doi: 10.2214/AJR.14.13459. PMID: 25905946; PMCID: PMC4889122.
- Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, Bedlack R, Goyal NA, Rutkove SB, Lange DJ, Rivner MH, Goutman SA, Ladha SS, Mauricio EA, Baloh RH, Simmons Z, Pothier L, Kassis SB, La T, Hall M, Evora A, Klements D, Hurtado A, Pereira JD, Koh J, Celnik PA, Chaudhry V, Gable K, Juel VC, Phielipp N, Marei A, Rosenquist P, Meehan S, Oskarsson B, Lewis RA, Kaur D, Kiskinis E, Woolf CJ, Eggan K, Weiss MD, Berry JD, David WS, Davila-Perez P, Camprodon JA, Pascual-Leone A, Kiernan MC, Shefner JM, Atassi N, Cudkowicz ME. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021 Feb 1.
